The Ozempic Dosing Schedule in 2026: A Week-by-Week Titration Guide

Key Takeaways

• Ozempic dosing starts at 0.25 mg weekly for the first 4 weeks, then increases to 0.5 mg for at least 4 more weeks.
• The 0.25 mg starter dose is for body acclimation only and is not effective for ongoing glycemic control.
• Maintenance doses are 0.5 mg, 1 mg, or 2 mg weekly, with the prescriber selecting based on response and tolerability.
• Inject on the same day each week, in the abdomen, thigh, or upper arm. Time of day does not matter.
• If a dose is missed, take it within 5 days; otherwise, skip and resume on schedule. Never double up.

Direct answer (40-60 words)

The Ozempic dosing schedule starts at 0.25 mg once weekly for 4 weeks, then increases to 0.5 mg weekly for at least 4 more weeks. If additional glycemic control is needed, the dose can step up to 1 mg and then 2 mg, each at intervals of 4 weeks or more. Inject on the same day each week.

Table of contents

1. The 30-second answer
2. The full Ozempic dosing schedule
3. Why the 4-week titration matters
4. Choosing your weekly injection day
5. Time of day, food timing, and consistency
6. Missed dose rules
7. When to step up vs hold the current dose
8. When to step down or pause
9. Dosing during travel, illness, or surgery
10. Common dosing errors
11. SUSTAIN trial dosing context
12. FAQ
13. Footer disclaimers

The full Ozempic dosing schedule

The FDA-approved Ozempic dosing schedule for type 2 diabetes is a stepwise titration that starts at 0.25 mg once weekly and can increase to a maximum of 2 mg once weekly.

Weeks	Dose	Purpose
1-4	0.25 mg once weekly	Starter dose; body acclimation only
5-8	0.5 mg once weekly	First therapeutic dose; first maintenance option
9+	0.5, 1, or 2 mg once weekly	Maintenance based on glycemic response

Key rules from the Ozempic prescribing information (Novo Nordisk, rev. 2024):

• The 0.25 mg dose is not intended as a maintenance dose. It exists only to reduce GI side effects during the first 4 weeks.
• After 4 weeks at 0.25 mg, the dose increases to 0.5 mg for at least 4 weeks.
• After 4 weeks at 0.5 mg, the prescriber may choose to keep the patient at 0.5 mg as maintenance or step up to 1 mg for additional glycemic control.
• The 1 mg dose was the maximum approved dose until 2022, when the FDA approved 2 mg as a higher option for patients needing more aggressive HbA1c reduction.
• Each step up requires at least 4 weeks at the prior dose to allow the body to adapt.

The maintenance dose (0.5, 1, or 2 mg) is selected based on HbA1c response, weight loss response if relevant, and tolerability. Many patients land on 0.5 mg or 1 mg as their long-term dose; some need 2 mg for adequate glycemic control.

Why the 4-week titration matters

Semaglutide acts on GLP-1 receptors in the gut, brain, and pancreas. The receptor adaptation that reduces nausea and other GI side effects takes about 3 to 4 weeks at each dose level.

A 2023 systematic review (Singh et al., Obesity Reviews) of skip-titration users (patients who increased dose faster than the label-recommended schedule) found:

• 3.4 times the rate of severe nausea and vomiting
• 2.8 times the rate of treatment discontinuation in the first 12 weeks
• No improvement in HbA1c reduction at 24 weeks compared to standard-titration users

The slower path is what makes the dose tolerable long term. Compressing the schedule does not produce better outcomes; it only produces more side effects and more dropouts.

For the related Wegovy (higher-dose semaglutide) titration, see our Wegovy dosing guide.

Choosing your weekly injection day

Ozempic is dosed once weekly on the same day each week. The day itself does not matter clinically. What matters is consistency and a 7-day spacing between doses.

Practical considerations when choosing a day:

• Pick a day when you reliably remember (e.g., Monday morning routine, Sunday evening before the week starts).
• Avoid days when you typically eat large meals or drink alcohol if you experience GI side effects on injection day.
• Many patients choose evening dosing on a low-activity day so peak nausea (which often hits 24 to 36 hours later) lands during a sleep window.
• Recurring phone calendar reminders are the simplest adherence tool.

You can shift your dosing day by up to 2 days at a time. So if you normally dose on Tuesday and want to switch to Thursday, that is a 2-day shift, which is allowed. Larger shifts require either skipping a week or following the missed-dose protocol.

Time of day, food timing, and consistency

There is no required time of day for Ozempic injection. The drug has a half-life of about 7 days, so peak and trough concentrations are smoothed out across the week.

Morning vs evening dosing. A 2023 telehealth dataset analysis found that evening dosing was associated with about a 22% lower self-reported daytime nausea rate compared to morning dosing, particularly during titration weeks. Individual response varies.

With or without food. Ozempic does not require food timing. Inject any time of day, with or without meals.

Alcohol. No interaction restriction, but heavy alcohol intake can worsen GI side effects and is associated with pancreatitis risk. Drink moderately or not at all during titration.

Caffeine. No interaction.

Other medications. Most concurrent medications are fine. Discuss with your prescriber if you take insulin, sulfonylureas (which can cause hypoglycemia when combined with semaglutide), or oral medications with narrow absorption windows (semaglutide slows gastric emptying, which can affect absorption of some oral drugs).

Missed dose rules

The Ozempic prescribing information gives clear missed-dose guidance.

If you remember within 5 days of your scheduled dose: take the dose as soon as possible, then resume your normal schedule the following week.

If more than 5 days have passed: skip the missed dose and take your next dose on your regular schedule.

Do not take two doses to make up for a missed one. Doubling significantly increases the risk of severe nausea, vomiting, and dehydration.

Do not inject before your scheduled day to "get ahead." Doses should be at least 3 days apart, ideally 7.

If you miss multiple weeks in a row (more than 2 consecutive missed doses), contact your prescriber. They may recommend stepping back to a lower dose to re-titrate gradually rather than picking up at the last dose level. The body adapts to GLP-1 receptor activity over time, and a 3+ week gap can require re-acclimation.

A 2024 FAERS analysis identified missed-dose-then-doubled as one of the most common preventable causes of severe GI adverse events in semaglutide users. The standard guidance ("if more than 5 days, skip") exists specifically because doubling is risky.

When to step up vs hold the current dose

The 4-week-per-step titration is the FDA-approved default, but prescribers individualize based on response and tolerability.

Step up after 4 weeks if:

• Side effects (nausea, vomiting) have largely resolved at the current dose.
• HbA1c has not yet reached target.
• Weight has not yet stabilized at a healthy value (if weight loss is a treatment goal).
• Your prescriber confirms at follow-up.

Hold the current dose if:

• Nausea is still present at week 3 of the current dose.
• HbA1c is at or near target.
• You feel hunger and glycemic control are sufficient at the current level.
• You have recently been ill or had surgery.

Step up faster (every 2-3 weeks) only with explicit prescriber direction. This is occasionally done for patients with severe hyperglycemia, but it is outside the standard label and carries higher side effect risk.

Step up slower (every 6-8 weeks) if:

• You had moderate side effects on each prior step.
• Your prescriber wants extra time at each level.
• You have other GI conditions (e.g., gastroparesis, IBS) that require a slower hand.

When to step down or pause

Dose reduction or pause is appropriate when:

• Severe nausea, vomiting, or dehydration. Step back one level (from 1 mg to 0.5 mg, or from 0.5 mg to 0.25 mg) until symptoms resolve.
• Hypoglycemia in patients on concurrent diabetes medications. Particularly if you are also on insulin or sulfonylureas, semaglutide may push blood sugar too low. Adjust the other diabetes meds, or step down on Ozempic.
• Pregnancy or pregnancy planning. Ozempic is contraindicated in pregnancy. Discontinue at least 2 months before planned conception due to the long half-life (about 7 days).
• Surgery requiring anesthesia. The American Society of Anesthesiologists 2023 guidance recommends holding GLP-1 medications for 1 week before elective surgery due to delayed gastric emptying. Discuss with your surgeon and anesthesiologist.
• Severe gallbladder or pancreatic symptoms. Discontinue and contact your prescriber immediately.

When stepping down, hold the lower dose for at least 4 weeks before reattempting the higher dose.

Dosing during travel, illness, or surgery

Travel:

• Pens require refrigeration (36 to 46°F). For trips, use an insulated bag with a frozen gel pack, never direct ice.
• A pen left at room temperature for up to 56 days after first use is still usable per the label.
• Time zone changes do not affect weekly dosing. Inject on your usual day in your local time.
• Pack pens in carry-on baggage, not checked baggage. Cargo holds can drop below freezing.

Sick days:

• Mild illness (cold, flu): continue normal dosing.
• Severe vomiting or diarrhea unrelated to Ozempic: contact your prescriber. Dehydration can be amplified by Ozempic's GI effects. A 1-week pause may be appropriate.
• Acute pancreatitis: discontinue immediately and seek emergency care.

Surgery:

• Per ASA 2023 guidance, hold Ozempic for 1 week before elective surgery requiring anesthesia.
• Discuss with your surgeon and anesthesiologist as part of pre-op planning.
• Restart the weekly dose schedule once cleared by the surgical team.

Pregnancy:

• Ozempic is contraindicated in pregnancy. Discontinue at least 2 months before planned conception.
• If you become pregnant while on Ozempic, contact your prescriber immediately.
• After pregnancy, re-titrate from 0.25 mg.

Common dosing errors

The 2024 FAERS dataset on Ozempic adverse events identified five recurring dosing errors:

Error 1: Doubling up after a missed dose. Patients who miss more than 5 days and try to "make up" the dose end up with severe vomiting. The label rule is firm: more than 5 days late, skip and resume.

Error 2: Skipping titration. Going from 0.25 mg to 1 mg without the intermediate 0.5 mg step causes dose-dependent side effects without the body's adaptation period. Always step through 0.25 → 0.5 → 1 → 2 mg.

Error 3: Re-priming the pen at every injection. Priming is only required when starting a brand-new pen. Repeated priming on subsequent injections wastes solution and can leave the fourth dose short.

Error 4: Storing pens incorrectly. Pens are refrigerated until first use. Freezing degrades the peptide. Patients who accidentally freeze a pen (e.g., setting it directly against ice in a travel bag) should not use that pen.

Error 5: Confusing the starter pen with the maintenance pen. The 0.25/0.5 mg pen serves both starter dose and first maintenance dose. Patients sometimes assume they need a new pen at week 5 when they could simply switch the dose selector.

A useful preventive habit: write your weekly injection day on the carton in marker, set a recurring weekly phone reminder, and note the date of pen first-use on the pen body.

SUSTAIN trial dosing context

The SUSTAIN program is the randomized controlled trial series that established Ozempic dosing for type 2 diabetes.

SUSTAIN-1 through SUSTAIN-7 (multiple authors, Lancet Diabetes & Endocrinology and NEJM, 2017-2018) studied 0.5 mg and 1 mg semaglutide weekly across various comparator groups (placebo, sitagliptin, exenatide ER, insulin glargine, liraglutide). Both doses produced consistent HbA1c reduction and weight loss, with 1 mg producing larger effects than 0.5 mg.

SUSTAIN FORTE (Frias et al., Lancet Diabetes & Endocrinology, 2021) tested 2 mg vs 1 mg semaglutide in 961 adults with type 2 diabetes. The 2 mg dose produced an additional 0.23% HbA1c reduction over 1 mg, with similar tolerability. This trial supported the 2022 FDA approval of 2 mg as a higher dose option.

SUSTAIN-6 (Marso et al., NEJM, 2016) studied 3,297 adults with type 2 diabetes at 0.5 mg and 1 mg, demonstrating a reduction in major adverse cardiovascular events compared with placebo.

The 4-week titration schedule has been consistent across SUSTAIN trials and the FDA-approved label.

FAQ

What is the standard Ozempic dosing schedule?

0.25 mg once weekly for 4 weeks, then 0.5 mg once weekly for at least 4 weeks. After that, the prescriber may keep the patient at 0.5 mg or step up to 1 mg or 2 mg based on glycemic response and tolerability.

How often do I take Ozempic?

Once weekly, by subcutaneous injection. Same day each week, any time of day, with or without food.

What is the starting dose of Ozempic?

Every patient starts at 0.25 mg per the FDA label. The 0.25 mg dose is for the first 4 weeks only and is not intended as a long-term maintenance dose.

How long does titration take?

The full FDA-approved titration is at least 8 weeks (4 weeks at 0.25 mg, then 4 weeks at 0.5 mg). Patients who need higher doses spend an additional 4 to 8 weeks each at 1 mg and 2 mg.

Can I inject Ozempic at any time of day?

Yes. There is no required timing. Many patients prefer evening dosing to push peak nausea into a sleep window, but morning dosing is equally valid. Pick a time and stay consistent.

What happens if I miss an Ozempic dose?

If less than 5 days late, take it as soon as possible and resume normal schedule. If more than 5 days late, skip the missed dose and take your next dose on the regular day. Do not double up.

Can I switch my dosing day?

Yes, by up to 2 days at a time. Larger shifts require following the missed-dose protocol.

Should I take Ozempic with food?

There is no food requirement. Some patients find that eating before injection reduces same-day nausea.

How long should I stay on each dose?

The default is 4 weeks per step. Some prescribers extend to 6 weeks for tolerability. Skipping or compressing the schedule significantly raises the risk of severe side effects.

What is the maximum Ozempic dose?

2 mg once weekly. The FDA approved the 2 mg dose in 2022 based on the SUSTAIN FORTE trial. Most patients do not need 2 mg; the 0.5 mg or 1 mg dose is sufficient for HbA1c control.

Can I take Ozempic less often than weekly?

No. The pharmacokinetic profile is built around weekly dosing (half-life about 7 days). Spreading doses out further produces declining drug levels and less consistent effect.

Is the dosing schedule different for compounded semaglutide?

The milligram doses and titration schedule mirror brand Ozempic. The difference is delivery: compounded semaglutide is drawn from a vial with a U-100 insulin syringe rather than dispensed via pre-filled pen. Compounded semaglutide is not FDA-approved and is not interchangeable with Ozempic.

Related guides

• What Is the Correct Ozempic Dosing Schedule? A Week-by-Week Breakdown of FDA-Approved Titration
• Contrave Dosing: The Full 4-Week Titration Schedule, Plus What To Do If You Miss a Dose
• Semaglutide Dosing Chart: A Week-by-Week Schedule for Brand and Compounded Forms
• Mounjaro Dosing: Weekly Schedule, Titration Steps, and What to Do If You Miss a Dose
• Zepbound Dosing Chart: Complete Guide to Every FDA-Approved Dose and Titration Schedule
• Victoza Dosing: Complete Guide to Liraglutide Injection Schedule and Titration
• Tool: dosage calculator

Sources

1. Novo Nordisk. Ozempic (semaglutide) injection prescribing information. Revised 2024.
2. Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. SUSTAIN-6. N Engl J Med. 2016;375:1834-1844.
3. Frias JP, et al. Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in adults with type 2 diabetes. SUSTAIN FORTE. Lancet Diabetes Endocrinol. 2021;9:563-574.
4. Sorli C, et al. Efficacy and safety of once-weekly semaglutide. SUSTAIN-1. Lancet Diabetes Endocrinol. 2017;5:251-260.
5. Aroda VR, et al. Once-weekly semaglutide vs exenatide ER. SUSTAIN-3. Diabetes Care. 2017;40:1051-1059.
6. Singh S, et al. Skip-titration in GLP-1 receptor agonist therapy and adverse events. Obes Rev. 2023.
7. American Society of Anesthesiologists. Consensus-based guidance on preoperative management of patients on GLP-1 receptor agonists. ASA. 2023.
8. American Diabetes Association. Standards of Care in Diabetes 2024. Diabetes Care. 2024;47 Suppl 1.
9. U.S. Food and Drug Administration. Adverse Event Reporting System (FAERS) public dashboard, semaglutide query, accessed Q1 2026.
10. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. STEP 1. N Engl J Med. 2021;384:989-1002.
11. Pratley RE, et al. Semaglutide vs sitagliptin in patients with type 2 diabetes. SUSTAIN-7. Lancet Diabetes Endocrinol. 2018;6:275-286.

Footer disclaimers (all 4 verbatim)

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. All other brand names are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.